These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36248788)

  • 1. PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
    Zhang X; Zhou Y; Chen H; Chen C; Lin Z; He LN; Du W; Chen T; Hong S; Fu S
    Front Immunol; 2022; 13():1015444. PubMed ID: 36248788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.
    Zhong YM; Yin K; Chen Y; Xie Z; Lv ZY; Yang JJ; Yang XN; Zhou Q; Wang BC; Zhong WZ; Gao LL; Zhou WB; Chen J; Tu HY; Liao RQ; Zhang DK; Zhang SL; Lu DX; Zheng HB; Zhang HH; Wu YL; Zhang XC
    Front Immunol; 2022; 13():951817. PubMed ID: 36263036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
    Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
    BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of immunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma.
    Pang LL; Liao J; Huang YH; Gan JD; Zhuang WT; Lv Y; Liang WT; Zhang L; Fang WF
    Int J Cancer; 2023 Jun; 152(11):2338-2350. PubMed ID: 36631999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy- A systematic review and meta-analysis.
    Li H; Ni M; Xue C; Li L; Huang R; Yang W; Hu A; An X; Shi Y
    Clin Immunol; 2022 Mar; 236():108927. PubMed ID: 35031491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
    Yu H; Chen P; Cai X; Chen C; Zhang X; He L; Zhou Y; Hong S; Zhang B
    Cancer Immunol Immunother; 2022 Mar; 71(3):637-644. PubMed ID: 34297160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer.
    Yu H; Chen P; Xia L; Fu S; Chen C; Zhang X; He L; Zhang B; Zhou Y; Hong S
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34750245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study.
    Li R; Liang H; Li J; Shao Z; Yang D; Bao J; Wang K; Xi W; Gao Z; Guo R; Mu X
    BMC Cancer; 2024 Jan; 24(1):107. PubMed ID: 38238648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
    Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
    Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50.
    Attili I; Valenza C; Santoro C; Antonarelli G; Trillo Aliaga P; Del Signore E; Catania C; Spitaleri G; Passaro A; de Marinis F
    Front Oncol; 2022; 12():980765. PubMed ID: 36033444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
    Qin B; Xin L; Liang C; Li L; Song Q; Long Y; Zhang X; Wang D; Shi W; Zhang J; Hu Y; Yang B; Xiong Q
    BMC Cancer; 2024 Jan; 24(1):100. PubMed ID: 38233798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of first-line PD-L1/PD-1 inhibitors in limited-stage small cell lung cancer: a multicenter propensity score matched retrospective study.
    Xie J; Xu K; Cai Z; Chen M; Jiang Y; Ye J; Lin X; Lv T; Zhan P
    Transl Lung Cancer Res; 2024 Mar; 13(3):526-539. PubMed ID: 38601454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis.
    Li H; Han H; Li C; Wu R; Wang Z; Wang Y; Zhan P; Lv T; Zhang F; Song Y; Liu H
    Ther Adv Med Oncol; 2023; 15():17588359231189430. PubMed ID: 37885460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study.
    Wei Q; Deng T; Wu J; Zeng H; Qi C; Tan S; Zhang Y; Huang Q; Pu X; Xu W; Li W; Tian P; Li Y
    BMC Cancer; 2024 Mar; 24(1):393. PubMed ID: 38549044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line immune-based combination therapies for advanced non-small cell lung cancer: A Bayesian network meta-analysis.
    Mao Z; Jiang P; Zhang Y; Li Y; Jia X; Wang Q; Jiao M; Jiang L; Shen Y; Guo H
    Cancer Med; 2021 Dec; 10(24):9139-9155. PubMed ID: 34747149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.
    Pérol M; Felip E; Dafni U; Polito L; Pal N; Tsourti Z; Ton TGN; Merritt D; Morris S; Stahel R; Peters S
    Ann Oncol; 2022 May; 33(5):511-521. PubMed ID: 35218887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.